Sarbajit Mukherjee, MD, MS, Assistant Professor, Roswell Park Comprehensive Cancer Center conducted a study to investigate the efficacy of a…
Browsing:
Prithvi Bose, an associate professor in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, focuses on…
In ASCO 2023, the highly anticipated results of the Adora study were unveiled, providing valuable insights into the efficacy and impact…
FOTIVDA is Aveo’s marketed product for treating advanced renal cell carcinoma, primarily used as a later line agent in the…
Philip McCarthy, MD, from Roswell Park Cancer Institute provided an overview of CAR T-cell therapy, focusing on its application in…
Caicun Zhou, MD, PhD – Tongji University Shanghai Pulmonary Hospital Sunvozertinib established itself as the leading targeted therapy for NSCLC…
Nicholas Robert, MD – Chief Medical Officer of Ontada Nicholas J. Robert, the chief medical officer at Ontada, is responsible…
Gamma Delta: Two Phase 1 INDs Approved Announces Jeff Liter CEO Luminary Therapeutics By Jeff Liter, MBS, CEO of Luminary…
Chimeric Antigen Receptor T-Cell Therapy: A Longitudinal Study Conner Johnson MD By Conner Johnson, MD Chimeric antigen receptor (CAR) T-cell…
Urothelial Cancer: What’s New in 2023? Targeted and Novel Therapies Nataliya Mar MD By Nataliya Mar, MD Good afternoon, everyone.…
Insights on Breast Cancer Treatment: Yuan Yuan, MD’s Discussion on Sacituzumab Govitecan and Other Novel Treatments By Yuan Yuan, MD,…
How effective is mosunetuzumab in treating lymphoma? – Elizabeth Budde, MD 2023 reviews new therapies By Elizabeth Budde, Md, PhD…
Lung Cancer Trials: Insights into Latest Clinical Trials in Thoracic Oncology – Expert Analysis from Ravi Salgia, MD By Ravi…
Belzutifan and other Novel Therapies in Genitourinary Oncology 2023 By Rana McKay, MD – University of California San Diego We’re…
iFrame is not supported! Inotuzumab and MRD Understanding the Importance of Targeted Therapy in Cancer Treatment Summarized from Van Huynh,…
MRD: Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia/Immunotherapy By Van Huynh, MD Today I spoke at…
Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia…
LW-02 Cartridge: Immunicom Therapy Amir Jafri CEO and Founder What is the LW-02 Cartridge Therapy? Immunicom was actually formed…
PRO in Pts With Rare Cancers: Pembrolizumab [2022] Â Patient reported Outcome (PRO) in patients with rare cancers (rare diseases)…
Follow real-world patients on their cancer journeys as they and their multidisciplinary clinical teams navigate barriers to receiving treatment with…
In this edition of The Onco’Zine Brief, Peter Hofland talking with Helen Sabzevari, the president of Precigen. Precigen is a…